Nuwellis, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
NUWE$5.24+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows
(in thousands)
| 2026 · 2025 | |||
|---|---|---|---|
| Operating Activities: | |||
| Net loss | $(4,541) | $(3,014) | |
| Adjustments to reconcile net loss to cash flows used in operating activities: | |||
| Depreciation and amortization | 38 | 73 | |
| Stock-based compensation expense | 25 | 67 | |
| Change in fair value of warrant liabilities | (26) | (40) | |
| Non-cash IP R&D from Rendiatech acquisition | 757 | - | |
| Changes in operating assets and liabilities: | |||
| Accounts receivable | (66) | 187 | |
| Inventory, net | 181 | (34) | |
| Other current assets | 293 | 41 | |
| Other assets Other liabilities | (171) | 45 | |
| Accounts payable and accrued expenses | 398 | 139 | |
| Net cash used in operating activities | (3,112) | (2,536) | |
| Investing Activities: | |||
| Purchases of property and equipment | (30) | - | |
| Purchase of intangible assets | (90) | - | |
| Cash paid for acquisition of Rendiatech, net of cash acquired | (164) | - | |
| Net cash used in investing activities | (284) | - | |
| Financing Activities: | |||
| Issuance of common stock and warrants from offering, net | 4,393 | - | |
| Non-cash Series J deemed dividend | 2 | - | |
| Net cash provided by financing activities | 4,395 | - | |
| Effect of exchange rate changes on cash | - | (2) | |
| Net increase (decrease) in cash and cash equivalents | 999 | (2,538) | |
| Cash and cash equivalents, and restricted cash - beginning of period | 1,190 | 5,095 | |
| Cash and cash equivalents, and restricted cash - end of period | $2,189 | $2,557 | |
| Supplemental cash flow information | |||
| Common stock issued as consideration in asset acquisition | $162 | $ | - |
| Transaction costs in accounts payable | $164 | $ | - |
| Deferred costs issued as consideration in asset acquisition | $313 | $ | - |
| Deemed dividend on Series J Preferred Stock | $2 | $1 | |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.